This inventor holds 1 USPTO granted patent. Top assignee: University of California. Active years: 2007.
Company Filing History:
Years Active: 2007
Title: Matthew E. Krummel: Innovator in T Cell Activation
Introduction
Matthew E. Krummel is a prominent inventor based in Berkeley, CA. He has made significant contributions to the field of immunology, particularly in enhancing T cell responses for therapeutic applications. His innovative work has the potential to impact treatments for tumors and chronic viral infections.
Latest Patents
Matthew E. Krummel holds a patent titled "Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling." This patent describes a method to increase T cell activation in response to antigens by administering binding agents that block CTLA-4 signaling. By inhibiting CTLA-4 signaling, the T cell response is released from inhibition, leading to enhanced immune responses. This advancement is particularly useful in the treatment of tumors, chronic viral infections, and as an adjuvant during immunization.
Career Highlights
Matthew E. Krummel is affiliated with the University of California, where he continues to conduct research and develop innovative solutions in immunology. His work has garnered attention for its potential applications in cancer therapy and vaccine development.
Collaborations
Some of his notable coworkers include James Patrick Allison and Dana R. Leach, who have also made significant contributions to the field of immunology.
Conclusion
Matthew E. Krummel's work in T cell activation represents a significant advancement in immunotherapy. His innovative approaches have the potential to transform treatment strategies for various diseases.